The COCOON trial: wrapping potent EGFR therapy in proactive supportive care Authors: Kushal Kriplani, Won Jin Jeon, Jeremy Cetnar, Chetan Vakkalagadda, Rajat Thawani Published: 2026 We are pleased to provide commentary on the COCOON trial by Cho et al. (1), a global randomized phase II study evaluating prophylactic dermatologic management in patients with previously untreated epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib. For nearly a decade, the standard of care (SoC) for locally advanced, metastatic, or unresectable NSCLC with classical EGFR mutations has been osimertinib monotherapy. More recently, two combination therapies showed efficacy: osimertinib with chemotherapy and amivantamab with lazertinib. The latter was studied in the frontline setting in EGFR-mutated NSCLC in the MARIPOSA trial, which demonstrated that amivantamab and lazertinib provided superior clinical outcomes to osimertinib alone. These efficacy gains come at the cost of increased toxicity: grade ≥3 adverse events (AEs) occurred in approximately 80% of patients treated with amivantamab-lazertinib compared with 52% of those receiving osimertinib (2). Dermatologic toxicities were particularly prominent: rash and paronychia occurred in approximately 64% and 69% of patients, respectively. Similar patterns of cutaneous toxicity have been consistently observed across amivantamab-based regimens, including the CHRYSALIS-2 and PALOMA-3 trials, underscoring dermatologic AEs as a class-defining challenge for EGFR- and MET-targeted bispecific antibody therapy (3,4). Given this substantial burden of skin toxicity associated with an otherwise highly effective regimen, there has been growing interest in proactive strategies to mitigate dermatologic AEs. The COCOON-DM intervention represents a comprehensive prophylactic approach that incorporates oral tetracycline (100 mg twice daily for weeks 1–12), topical clindamycin applied to the scalp (weeks 13–52), a 4% chlorhexidine wash, and daily ceramide-based moisturization. In this study, 201 patients were randomized 1:1 to enhanced dermatologic management (COCOON-DM; n=99) or SoC dermatologic management (n=102). At a median follow-up of 7.1 months, the incidence of grade ≥2 dermatologic AEs by week 12 was significantly lower in the COCOON-DM arm compared with SoC (42% vs. 75%; odds ratio 0.24; 95% confidence interval: 0.13–0.45; P<0.0001). The most pronounced reductions were observed in dermatologic toxicities involving the face and body (excluding paronychia; 26% vs. 60%) and the scalp (10% vs. 26%). Lung cancer remains one of the most diagnosed cancers and the leading cause of cancer-related mortality worldwide, accounting for approximately 2.5 million new cases and 1.8 million deaths in 2025 (5). Among histologic subtypes, adenocarcinoma predominates, and within this group, EGFR represents the most frequently actionable oncogenic driver. Limitations Despite its encouraging findings, several limitations of the COCOON trial warrant careful consideration. The open-label design introduces potential performance and detection bias, particularly for subjective endpoints such as patient-reported outcomes and clinician-graded dermatologic toxicity. This concern is amplified by the exclusive use of a digital health tool in the intervention arm, which may independently affect symptom reporting, adherence, and patients’ perceptions of care, thereby introducing a co-intervention effect that complicates attribution of observed outcomes solely to the antibiotic strategy. The lack of blinding further increases the risk of bias. Patients receiving enhanced dermatologic care alongside a digital support tool may report improved symptoms due to increased attention and perceived benefit rather than true pharmacologic effect. Similarly, investigators aware of treatment allocation may unconsciously grade dermatologic events differently, particularly for subjective measures such as rash severity or global impression scores. Methodologically, reliance on dermatologic AEs—graded using CTCAE criteria—as the sole primary endpoint raises important questions regarding clinical relevance. CTCAE grading for skin toxicities has limited psychometric validation and often correlates poorly with treatment modifications or discontinuation decisions in routine practice. Additionally, the trial did not evaluate oncologic outcomes such as progression-free survival, overall survival, or rates of treatment interruption and dose reduction due to dermatologic toxicity. Without such data, it remains unclear whether the observed reduction in grade ≥2 skin AEs translates into improved treatment adherence or meaningful survival benefits. Beyond methodological concerns, the COCOON regimen raises practical issues related to feasibility and long-term safety. The multi-component intervention adds complexity to an already intensive cancer treatment course. Prolonged antibiotic exposure—specifically 12 weeks of oral tetracycline—raises legitimate concerns regarding antimicrobial resistance, which was not assessed in the trial. Existing data demonstrate that tetracyclines can induce durable alterations in the skin microbiome, including the emergence of antibiotic-resistant staphylococcal species (6). Given the broader public-health implications of antimicrobial resistance, the population-level impact of widespread adoption of prolonged prophylactic antibiotics deserves careful scrutiny. Strengths Notwithstanding these limitations, the COCOON trial possesses several notable strengths. The investigator’s effort to conduct a supportive care clinical trial for a drug that has significantly improved survival has not been common. Randomization across multiple international sites reduces selection bias and enhances generalizability. The study addresses a clear and clinically relevant unmet need, as prior trials of amivantamab-lazertinib reported dermatologic toxicity rates exceeding 80%, with approximately 10% of patients discontinuing therapy due to AEs. The incorporation of validated patient-reported outcome instruments, such as the Skindex-16 and the Patient Global Impression of Severity, strengthens the assessment of patient experience, as patient-reported outcomes can be subject to bias without such tools. The magnitude of benefit observed, a 33% absolute reduction in grade ≥2 dermatologic AEs, is clinically meaningful and was achieved using inexpensive, widely available generic interventions. The integration of a digital health platform reflects contemporary approaches to supportive care and may facilitate real-world implementation of complex prophylactic regimens. Importantly, the rapid incorporation of COCOON findings into National Comprehensive Cancer Network clinical practice guidelines underscores the perceived clinical relevance and immediate applicability of the results. Conclusions The COCOON trial represents an important step forward in addressing the dermatologic toxicity burden associated with amivantamab-lazertinib, a regimen that has redefined first-line therapy for EGFR-mutant NSCLC. While the demonstrated reduction in skin toxicity supports adoption of proactive dermatologic management in routine practice, clinicians should engage patients in shared decision-making that balances symptomatic benefit against potential risks, particularly those related to prolonged antibiotic exposure. Future phase III studies are needed to determine whether enhanced prophylactic dermatologic strategies translate into improved oncologic outcomes through better treatment adherence, fewer dose modifications, and longer duration of therapy. Additionally, studies exploring abbreviated antibiotic courses or simplified regimens may help preserve dermatologic benefit while mitigating concerns about antimicrobial resistance. Until such data are available, the COCOON regimen is a reasonable, individualized supportive care strategy for patients receiving amivantamab-based therapy. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Thoracic Disease. The article did not undergo external peer review. Funding: None. Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0445/coif). C.V. reports consulting or advisory role (Takeda, Merus, AstraZeneca, Johnson & Johnson, and Lilly); and honoraria (Binaytara, and DAVA Oncology). R.T. reports consulting or advisory role (Catalyst Pharmaceuticals, Nuvation, Pfizer, Johnson & Johnson/Janssen, Bristol Myers Squibb, Bayer, Boehringer Ingelheim, Regeneron, and AbbVie); honoraria (MJH Life Sciences Travel); and accommodations and expenses (Black Diamond Therapeutics). The other authors have no conflicts of interest to declare. References Associated Data Supplementary Materials The article’s supplementary files as